ETON Eton Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1710340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY100.6%
TTM net income YoY846.2%
TTM EPS YoY703.3%
Revenue 3-yr CAGR62.6%
Net income 3-yr CAGR181.6%
Margins
Gross margin69.2%
Operating margin28.8%
Net margin35.3%
FCF margin27.1%
EBITDA margin31.4%
Returns
ROE90.6%
ROA38.1%
ROIC (approx.)115.0%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets44.7%
Debt / equity0.27x
Current ratio1.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio8.8%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $57.92M | $37.59M | $24.27M | $21.28M | $22.46M | $18.93M | $17.28M | $11.65M |
| Cost of revenue | $13.62M | $12.18M | $9.53M | $8.18M | $14.60M | $7.00M | $7.42M | $5.17M |
| Gross profit | $44.30M | $25.41M | $14.73M | $13.10M | $7.86M | $11.92M | $9.86M | $6.48M |
| R&D expense | $5.27M | $993,000 | $1.88M | $1.78M | $1.11M | $3.71M | $1.16M | -$871,000 |
| SG&A expense | $16.02M | $11.63M | $10.45M | $8.86M | $8.11M | $9.69M | $9.17M | $6.72M |
| Operating income | $23.01M | $12.79M | $2.41M | $2.46M | -$1.36M | -$1.48M | -$470,000 | $629,000 |
| Interest expense | — | $1.01M | $1.14M | $1.21M | $1.21M | $1.20M | $1.16M | $1.33M |
| Pretax income | $22.36M | $11.72M | $1.57M | $1.41M | -$1.96M | -$2.52M | -$1.50M | -$511,000 |
| Income tax | -$12.89M | $140,000 | $20,000 | -$69,000 | -$28,000 | $66,000 | $74,000 | $87,000 |
| Net income | $35.25M | $11.58M | $1.55M | $1.48M | -$1.93M | -$2.58M | -$1.57M | -$598,000 |
| EBITDA | $23.03M | $14.18M | $3.54M | $3.48M | -$1.35M | -$470,000 | $543,000 | $984,000 |
| EPS (basic) | 1.23 | 0.42 | 0.06 | — | -0.07 | -0.10 | -0.06 | — |
| EPS (diluted) | 1.06 | 0.35 | 0.05 | — | -0.07 | -0.10 | -0.06 | — |
| Weighted avg. shares (diluted) | 33.26M | 32.79M | 31.55M | — | 26.89M | 26.89M | 26.89M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.63M | $26.84M | $19.66M | $25.94M | $37.12M | $25.38M | $17.42M | $14.94M |
| Receivables | $26.43M | $24.89M | $13.41M | $11.76M | $13.08M | $14.45M | $16.40M | $5.36M |
| Inventory | $11.08M | $10.14M | $14.47M | $15.42M | $16.86M | $23.79M | $13.62M | $15.23M |
| Current assets | $96.78M | $68.60M | $53.24M | $60.58M | $72.00M | $68.44M | $49.96M | $41.02M |
| PP&E, net | $338,000 | $352,000 | $372,000 | $326,000 | $294,000 | $18,000 | $22,000 | $34,000 |
| Intangibles | $44.28M | $45.68M | $43.74M | $30.88M | $31.88M | $32.88M | $33.88M | $34.88M |
| Total assets | $157.27M | $115.81M | $97.71M | $92.11M | $104.51M | $101.68M | $84.03M | $76.12M |
| Current liabilities | $54.09M | $45.12M | $44.18M | $38.49M | $44.18M | $38.60M | $25.35M | $19.95M |
| Short-term debt | $11.84M | $8.82M | $11.81M | $8.79M | $2.78M | $2.77M | — | $0 |
| Long-term debt | $11.23M | $19.08M | $18.94M | $21.77M | $27.59M | $27.41M | $29.99M | $29.81M |
| Total debt | $23.07M | $27.90M | $30.75M | $30.56M | $30.37M | $30.18M | $29.99M | $29.81M |
| Total liabilities | $70.35M | $69.22M | $67.09M | $65.96M | $81.38M | $77.72M | $59.58M | $51.70M |
| Shareholders' equity | $86.92M | $46.59M | $30.61M | $26.15M | $23.13M | $23.96M | $24.45M | $24.43M |
| Net debt | -$32.56M | $1.06M | $11.09M | $4.62M | -$6.75M | $4.80M | $12.57M | $14.88M |
| Shares outstanding | 28.83M | 28.29M | 27.36M | 27.05M | 26.82M | 26.82M | 26.82M | 26.71M |
| Cash flow statement | ||||||||
| Operating cash flow | $35.24M | $7.25M | $7.41M | -$11.55M | $12.03M | $7.96M | $2.09M | -$765,000 |
| Capital expenditure | $13,000 | -$5,000 | $75,000 | $49,000 | $284,000 | $0 | $0 | $12,000 |
| Free cash flow | $35.23M | $7.26M | $7.33M | -$11.60M | $11.74M | $7.96M | $2.09M | -$777,000 |
| Investing cash flow | -$3.24M | $5,000 | -$15.07M | -$49,000 | -$284,000 | $0 | $0 | -$38.13M |
| Financing cash flow | -$3.22M | -$76,000 | $1.39M | $421,000 | $0 | $0 | $394,000 | $33.57M |
| Depreciation & amortization | $21,000 | $1.39M | $1.13M | $1.02M | $8,000 | $1.00M | $1.01M | $355,000 |
| Stock-based compensation | $3.31M | $1.47M | $1.52M | $1.12M | $1.09M | $2.10M | $1.20M | $782,000 |
Free plan shows the latest 8 periods; Pro shows all 36 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.